SHYNDEC(SH:600420) Ge Long Hui A P P·2026-02-11 11:12Core Viewpoint - China National Pharmaceutical Modern (600420.SH) announced participation in the national centralized procurement for drugs whose agreements have expired, with 51 drugs from the company and its subsidiaries proposed for selection in the continuation procurement [1] Group 1: Procurement Details - The continuation procurement is organized for drugs from the first to eighth batches of national centralized procurement agreements that have expired [1] - The procurement cycle for the selected drugs will last from the execution of the selection results until December 31, 2028 [1] - The procurement office has not disclosed specific supply prices and quantities for the selected drugs [1] Group 2: Market Impact - Overall, the continuation procurement is expected to maintain price stability, with some drug prices potentially decreasing further [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed procurement volume [1] - The signing of sales contracts for the selected drugs is anticipated to solidify the company's existing market share and enhance its brand influence and market competitiveness [1] - The aforementioned matters are not expected to have a significant impact on the company's current operating performance [1]